From 02138ee60d904cc95faf6b9936b55f150914efbb Mon Sep 17 00:00:00 2001 From: Borja Robert Date: Mon, 19 Feb 2024 16:06:36 +0100 Subject: [PATCH] Auto saved by Logseq --- pages/STOP2030___Web.md | 4 ++-- 1 file changed, 2 insertions(+), 2 deletions(-) diff --git a/pages/STOP2030___Web.md b/pages/STOP2030___Web.md index 30ba0142..bfd2ea87 100644 --- a/pages/STOP2030___Web.md +++ b/pages/STOP2030___Web.md @@ -13,11 +13,11 @@ - Develop a model for sustainable supply and costing - Model the impact of different use cases and scenarios - Pilot antihelmintic resistance surveillance based on genetic epidemiology - - ## Objetivos y logros de los proyectos STOP previos en background + - ## Objetivos y logros de los proyectos STOP previos (en background) - Qualification at EMA for art. 58 - Safety of IVM up to 600μg/kg alone and in coformulation with albendazole - Demonstrated efficacy agrainst T. trichiura in a pivotal trial in Sub-Saharan Africa - - FDC of ivm/alb has the lowest level of investment risk of all candidates for Combination for STH treatment (STH Drug Combinations Expert Meeting, BMGF, April 2016) + - ## FDC of ivm/alb has the lowest level of investment risk of all candidates for Combination for STH treatment (STH Drug Combinations Expert Meeting, BMGF, April 2016) - Main results of previous STOP projects: ALIVE pivotal Trial - Investigadores principales de cada uno de los partners - Timeline y milestones (cuáles se han cumplido?)